リコンビナント活性化因子VIIの低濃度は,アベラシマブin vitroによって誘発された粘性弾性試験パラメータの変化を逆転させることで,凝固パターンを正常化する
Yasser Khder1, Serge Côté2, Klaus Peter Hoffmann3
1Anthos Therapeutics, Cambridge, Massachusetts, USA.
Research and practice in thrombosis and haemostasis
|August 21, 2025
まとめ
リコンビネント活性化因子VIIa (rFVIIa) の低用量は,FXI/ FXIa阻害剤であるアベラシマブの抗凝固効果を効果的に逆転させた. これは,rFVIIaがアベラシマブで治療された患者の出血を制御することを示唆しています.
科学分野:
- 血液学
- 薬理学について
背景:
- 複合活性因子VIIa (rFVIIa) は,因子XI欠乏症の出血に使用されます.
- アベラシマブは,抗凝固性を持つXI/ XI因子阻害剤です.
研究 の 目的:
- 低用量のrFVIIaがアベラシマブ誘発の凝固変化に逆らえるかどうかを評価する.
- rFVIIaの有効性を評価するには,回転性血栓弾性測定法 (ROTEM) を用いる.
主な方法:
- 健康なドナーの全血はアベラシマブで処理された.
- rFVIIa または 車両の追加
- 凝固のパラメータ (凝固時間,凝固形成時間,アルファ角度) は,ROTEMを用いて測定された.
主要な成果:
- アベラシマブは凝固時間を大幅に延長し,アルファ角を減少させた.
- 低濃度のrFVIIa (0. 5 - 1μg/ ml) は,アベラシマブによるこれらの効果を逆転させた.
- ROTEMのパラメータは rFVIIaの加算で正常化した.
結論:
- 低用量のrFVIIaは,アベラシマブの凝固への影響を効果的に修正する.
- rFVIIaは,アベラシマブ治療を受けている患者の出血管理のための潜在的な治療法です.
さらに関連する動画
関連する概念動画
Anticoagulant Drugs: Low-Molecular-Weight Heparins
893
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
893
Clot Retraction and Fibrinolysis
6.8K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.8K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Extrinsic and Intrinsic Pathways of Hemostasis
9.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.2K
Coagulation
374
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
374


